Comparative Cardiovascular Outcomes in Acalabrutinib vs. Zanubrutinib in B-Cell Malignancies: A TriNetX Data Study
Current Oncology · 2026
DOI: 10.3390/curroncol33100641 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Current Oncology, 2026. Verfasst von Maan Awad und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, West Virginia University Heart and Vascular Institute, Morgantown, WV 26506, USA. Hauptthemen laut MEDLINE: Benzamides, Pyrazines, Protein Kinase Inhibitors, Cardiovascular Diseases. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Next-generation Bruton’s tyrosine kinase inhibitors (BTKis) such as acalabrutinib and zanubrutinib have improved treatment outcomes in B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström macroglobulinemia (WM), while reducing off-target toxicities compared to ibrutinib. However, their comparative cardiovascular safety profiles remain poorly characterized. This study evaluates real-world cardiovascular and clinical outcomes between zanubrutinib and acalabrutinib using a large multi-center database. We conducted a retrospective cohort study using the TriNetX Research Network (October 2017–December 2024) including adult patients with CLL, MCL, WM, or small B-cell lymphoma treated with zanubrutinib or acalabrutinib. Patients with prior exposure to other BTKis were excluded. After 1:1 propensity score matching, 2887 patients were included in each cohort. We assessed one-year outcomes including new-onset atrial fibrillation/flutter, cerebral infarction, hypertension, and all-cause mortality using Cox proportional hazards modeling. The rate of AF/flutter events observed in the zanubrutinib group (4.05%) was numerically lower compared to the acalabrutinib group (5.25%). Time-to-event analysis did not demonstrate a statistically significant difference in AF risk over time (HR 0.777, 95% CI 0.597–1.012; p = 0.06), which was similar in binary analysis (OR 0.761, 95% CI 0.581–0.997; p = 0.05). Cerebral infarction rates were similar between groups (1.09% vs. 1.12%), with no significant difference in time-to-event analysis (HR 0.984, 95% CI 0.596–1.626; p = 0.95) or binary analysis (p = 0.91). There was no significant difference in onset of hypertension in the zanubrutinib cohort (HR 1.199, 95% CI 0.957–1.501; p = 0.11) All-cause mortality was not statistically significant between the two groups (HR 0.865, 95% CI 0.740–1.012; p = 0.07). In this large, real-world analysis, fewer AF/flutter events were observed with zanubrutinib at one year; however, time-to-event analysis did not demonstrate a statistically significant difference in AF risk over time. Notably, hypertension, cerebral infarction, and all-cause mortality occurred at similar rates. This suggests zanubrutinib and acalabrutinib share similar cardiovascular safety profiles overall. However these findings are hypothesis-generating and require prospective validation before definitive conclusions about cardiovascular risk can be drawn.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, West Virginia University Heart and Vascular Institute, Morgantown, WV 26506, USA.
- Department of Medicine, West Virginia University, Parkersburg, WV 26104, USA.
- Department of Medicine, West Virginia University, Morgantown, WV 26506, USA.
- Department of Medicine, Willis Knighton Health System, Shreveport, LA 71103, USA.
- Department of Internal Medicine, Mamata Medical College, Khammam 507002, Telangana, India.
- Department of Internal Medicine, Division of Cardiology, Indiana University, Indianapolis, IN 46202, USA.
ORCID-Profile: Maan Awad, Syed Ahmad, Abdulrahman Murshid
Zitieren
APA
Awad, M., Tah, S., Ahmad, S., Patel, H., Kumsi Sreedhar, P., Lingamsetty, S. S. P., Murshid, A., & Patel, B. (2026). Comparative Cardiovascular Outcomes in Acalabrutinib vs. Zanubrutinib in B-Cell Malignancies: A TriNetX Data Study. Current Oncology. https://doi.org/10.3390/curroncol33100641
Vancouver
Awad M, Tah S, Ahmad S, Patel H, Kumsi Sreedhar P, Lingamsetty SSP, et al. Comparative Cardiovascular Outcomes in Acalabrutinib vs. Zanubrutinib in B-Cell Malignancies: A TriNetX Data Study. Current Oncology. 2026. doi:10.3390/curroncol33100641
BibTeX
@article{Awad2026,
author = {Awad, Maan and Tah, Sunanda and Ahmad, Syed and Patel, Het and Kumsi Sreedhar, Prajwal and Lingamsetty, Shanmukh Sai Pavan and Murshid, Abdulrahman and Patel, Brijesh},
title = {Comparative Cardiovascular Outcomes in Acalabrutinib vs. Zanubrutinib in B-Cell Malignancies: A TriNetX Data Study},
journal = {Current Oncology},
year = {2026},
doi = {10.3390/curroncol33100641}
}
EUVIMED